Noninvasive Characterization of Hepatic Lesions by Means of Glypican-3–Directed PET/CT
Glypican-3 (GPC-3) is a cell-surface heparan sulfate proteoglycan that is preferably overexpressed in hepatocellular carcinoma (HCC). Thus, it serves to differentiate HCC from other benign or malignant hepatic lesions ([1][1]–[3][2]). Recently, a selective GPC3-targeting peptide radiolabeled with
Authors
- Ralph A. Bundschuh (ORCID: https://orcid.org/0000-0001-7291-9372)
- Bruno Märkl (ORCID: https://orcid.org/0000-0002-7704-850X)
- Nic G. Reitsam (ORCID: https://orcid.org/0000-0002-0070-3158)
- Martin Trepel
- Thomas Kröncke (ORCID: https://orcid.org/0000-0003-4889-1036)
- Constantin Lapa (ORCID: https://orcid.org/0000-0001-7536-2207)
- Alexander Dierks
- Helen Scholtissek
Institutions
- Technische Hochschule Augsburg (DE)
- University of Augsburg (DE)
- University Hospital Augsburg (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-04-03
- DOI
- https://doi.org/10.2967/jnumed.124.269290
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97